From: In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis
Diagnosis confirmed clinically and biochemically | 100% |
Removal of potential culprit drugs | 100% |
Exclusion of adrenal / thyroid pathology | 100% |
Documentation of fluid balance status and charts | 92% |
Documentation of 48 h fluid restriction prior to starting Tolvaptan | 96% |
Tolvaptan initiation according to Trust policy | 96% |
Na level monitoring before/after initiation as per recommendations | 96% |